{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-000864","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2025-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.952115+00:00","generated_at":"2026-05-26T21:03:01.221890+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Edesa Biotech reports Q1 FY2025 net loss of $1.6M; raises $15M in private placement","bullets":["Net loss of $1.6M ($0.48/share) compared to $1.7M ($0.54/share) in prior year quarter.","R&D expenses rose to $1.0M (from $0.7M) on increased manufacturing costs for paridiprubart.","Cash at Dec 31, 2024 was $1.6M; subsequent $15M preferred/common private placement closed.","Company plans IND for EB06 (anti-CXCL10) in vitiligo Phase 2; FDA submission mid-2025.","EB05 (paridiprubart) ARDS study fully funded by U.S. government; top-line vitiligo data expected within 12-18 months post clearance."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-000864","json":"https://secwatch.observer/filing/0001171843-25-000864.json","markdown":"https://secwatch.observer/filing/0001171843-25-000864.md","text":"https://secwatch.observer/filing/0001171843-25-000864.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000117184325000864/0001171843-25-000864-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000117184325000864/f8k_021425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T21:03:01.221890+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}